Xerox Corporation (XRX) traded within a range of $6.93 to $7.04 after opening the day at $6.94. The company has seen its stock increase in value by 22.09% so far this year. The stock was up close to 1.3% on light volume in last trading session and closed at $7.02 per share. After the recent gain, the stock is currently holding -4.06% below its 52 week high of $11.39 and 29.81% above its 12-month low of $6.46. The shares are up by over 12.31% in the last three months, and the RSI indicator value of 65.65 is neither bullish nor bearish, tempting investors to stay on the sidelines.
Xerox Corporation provides business process and document management solutions worldwide. Its Services segment offers business process outsourcing services, such as customer care, transaction processing, finance and accounting, human resources, communication and marketing, and consulting and analytics services, as well as services in the areas of healthcare, transportation, financial services, retail, and telecommunications areas. This segment also provides document outsourcing services comprising managed print services, including workflow automation and centralized print services. The companys Document Technology segment offers desktop monochrome and color printers, multifunction printers, copiers, digital printing presses, and light production devices; and production printing and publishing systems for the graphic communications marketplace and large enterprises. Its Other segment sells paper, wide-format systems, global imaging systems network integration solutions, and electronic presentation systems. The company sells its products and services directly to its customers; and through its sales force, as well as through a network of independent agents, dealers, value-added resellers, systems integrators, and the Web. Xerox Corporation was founded in 1906 and is headquartered in Norwalk, Connecticut.
ARIAD Pharmaceuticals, Inc. (ARIA) managed to rebound with the stock climbing 0.23% or $0.06 to close the day at $23.7 on active trading volume of 11.93M shares, compared to its three month average trading volume of 10.24M. The Cambridge Massachusetts 02139 based company has been outperforming the biotechnology group over the past 52 weeks, with the stock gaining 349.62%, compared to the industry which has advanced 3.8% over the same period. With RSI of 89.74, the stock should still continue to rise and get closer to its one year target estimate of $20.63, making it a hold for now.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
Exxon Mobil Corporation (XOM) dropped $-1.08 to close the day at a new closing price of $86.28, a -1.24% decrease in value from its previous closing price that moved the stock 24.85% above its 52 week low of $72.61. A total of 11.79M shares exchanged hands during the day compared with its three month average trading volume of 10.78M. The stock, which fluctuated between $86.05 and $87.41 during the day, currently situated -8.13% below its 52 week high. The stock is down by -5.07% in the past one month and up by 0.58% over the past three months. With a one year target estimate of $88.64 and RSI of 39.16, the stock still has upside potential, making it a hold for now.
Exxon Mobil Corporation explores for and produces crude oil and natural gas in the United States, Canada/South America, Europe, Africa, Asia, and Australia/Oceania. It also manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and specialty products; and transports and sells crude oil, natural gas, and petroleum products. As of December 31, 2015, the company had approximately 35,909 gross and 30,114 net operated wells. Exxon Mobil Corporation was founded in 1870 and is headquartered in Irving, Texas.